Aplasia medular adquirida, experiencia en un hospital público de referencia / Acquired aplastic anemia: experience in a public hospital
Rev. méd. Chile
;
146(2): 175-182, feb. 2018. tab, graf
Artículo
en Español
| LILACS
| ID: biblio-961375
ABSTRACT
Background:
The first line treatment for patients < 40 years old with aplastic anemia (AA) is allogeneic HLA-identical sibling donor transplantation (SCT). Immunosuppressive therapy (IST) with a combination of Thymoglobuline (ATG) and cyclosporine is used for older patients or those without a donor. Five year overall survival (OS) for both therapies is > 70%.Aim:
To report the experience with SCT and ATG for AA in a public hospital. Patients andMethods:
AA was diagnosed in 42 patients between 1998 and 2016, according to Camitta criteria. Thirty eight (90%) received treatment, 7 (18%) under 40 years old received SCT, and 31 (82%) IST. The rest were not treated. OS was calculated from date of diagnosis until last control, death or loss from follow up.Results:
Complete or partial hematologic response, was obtained in 71% and 58% of cases with SCT and IS, respectively. Five year OS was 71% and 55% with SCT and IST, respectively. No difference in response was observed between horse and rabbit ATG.Conclusions:
SCT from an HLA-identical sibling donor had a high response rate and survival. IST instead, had a lower response and survival, due to an initial high mortality rate.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Ciclosporina
/
Trasplante de Células Madre
/
Inmunosupresores
/
Anemia Aplásica
/
Suero Antilinfocítico
Límite:
Adolescente
/
Adulto
/
Anciano
/
Aged80
/
Humanos
Idioma:
Español
Revista:
Rev. méd. Chile
Asunto de la revista:
Medicina
Año:
2018
Tipo del documento:
Artículo
País de afiliación:
Chile
Institución/País de afiliación:
Hospital del Salvador/CL
Similares
MEDLINE
...
LILACS
LIS